TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL
TIC10 通过调节 Foxo3a 和 TRAIL 发挥抗肿瘤作用
基本信息
- 批准号:8741956
- 负责人:
- 金额:$ 0.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-30 至 2014-10-31
- 项目状态:已结题
- 来源:
- 关键词:14-3-3 ProteinsAddressAdvanced Malignant NeoplasmApoptosisApoptoticBindingBiologicalBiological AvailabilityBloodBlood - brain barrier anatomyBrainBrain NeoplasmsCancer ModelCell Death InductionCell NucleusClinicClinicalClinical TrialsColon CarcinomaColorectal CancerConsensus SequenceCytoplasmDataDevelopmentDisease ProgressionFamilyFamily memberFutureGenesGenetic TranscriptionHalf-LifeHumanLaboratory StudyLiteratureLymphomaMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of lungMediatingMolecularMolecular TargetNormal CellNuclear TranslocationPathway interactionsPatientsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPost-Translational Protein ProcessingPrimary NeoplasmProductionPropertyProteinsRecombinant ProteinsRecombinantsRegulationRoleSafetySamplingScienceSerumSignal TransductionSignaling MoleculeSpecificitySpecimenTNF-related apoptosis-inducing ligandTNFSF10 geneTestingTherapeutic AgentsToxic effectTranscriptional ActivationTransgenic MiceTranslatingTranslationsValidationWorkXenograft procedureaggressive therapyanti-cancer therapeuticantitumor agentbasecancer cellcofactorcolon cancer cell linecostimprovedin vivoinsightkillingsmalignant breast neoplasmmemberneoplastic cellnoveloverexpressionpre-clinicalpromoterpublic health relevanceresponsesmall moleculetherapy resistanttranscription factortranslational medicinetumortumor progressiontumor xenograft
项目摘要
DESCRIPTION (provided by applicant): The potency and safety of TRAIL has prompted clinical trials with the recombinant protein as a novel treatment for human cancer. While TRAIL is very active in killing tumor cells, recombinant TRAIL possesses drug properties that limit its efficacy such as short serum half-life, instability, and the inability to cross the intact blood-brin barrier. To overcome these limitations we identified a small molecule inducer of the TRAIL gene, TIC10 that is superior to recombinant TRAIL in terms of stability, bioavailability, ability to cros the blood-brain barrier, cost of production, and spectrum of activity. Importantly, our data shows that TIC10 is highly active in several aggressive and therapy-resistant cancers. On a mechanistic level, TIC10 causes potent antitumor effects and TRAIL-induction that is mediated by the transcription factor Foxo3a, which directly regulates the TRAIL gene promoter. Furthermore, we found that TIC10 results in the dual inactivation of Akt and ERK, thereby inhibiting their constitutive phosphorylation of Fox3a and potentiating its translocation to the nucleus and binding to the TRAIL gene promoter (Allen et al, Science Translational Medicine, In Press, 2013). We hypothesize that TIC10 induces potent antitumor effects that require Akt- and ERK-mediated Foxo3a nuclear translocation and transcriptional activation of the TRAIL gene. To address the hypothesis we propose the following specific aims: Specific Aim #1: Identify TIC10-induced effects on Foxo3a expression, phosphorylation, and subcellular localization; Specific Aim #2: Elucidate the role of Akt and ERK kinases in the mechanism of action of TIC10; Specific Aim #3: Determine the differential regulation of TRAIL gene transcription by FOXO family members. These studies will create a comprehensive molecular understanding of how TIC10 harnesses Foxo3a to achieve its potent antitumor activity and also has the potential to undercover novel regulatory mechanisms of Foxo3a activity that are biologically significant. Preclinical cancer models including orthotopic xenografts and transgenic mice along with primary human tumor specimens will substantiate the efficacy and validate the mechanistic findings regarding TIC10 and Foxo3a. Together, these studies will elucidate key and novel regulatory mechanisms involving Foxo3a with the first-in-class molecule TIC10 to yield insight regarding its mechanism of action as well as in clinical samples in the context of colon cancer disease progression. Our studies will facilitate the clinical translation of a novel anti-cancer therapeutic agent through further development in preclinical laboratory studies.
描述(由申请人提供):TRAIL 的效力和安全性促使重组蛋白作为人类癌症的新型治疗方法进行临床试验。虽然 TRAIL 在杀死肿瘤细胞方面非常活跃,但重组 TRAIL 的药物特性限制了其功效,例如血清半衰期短、不稳定以及无法穿过完整的血盐屏障。为了克服这些限制,我们鉴定了 TRAIL 基因的小分子诱导剂 TIC10,它在稳定性、生物利用度、穿过血脑屏障的能力、生产成本和活性谱方面优于重组 TRAIL。重要的是,我们的数据表明 TIC10 在几种侵袭性和难治性癌症中高度活跃。在机制水平上,TIC10 产生有效的抗肿瘤作用和由转录因子 Foxo3a 介导的 TRAIL 诱导作用,Foxo3a 直接调节 TRAIL 基因启动子。此外,我们发现 TIC10 导致 Akt 和 ERK 双重失活,从而抑制 Fox3a 的组成型磷酸化,并增强其转位至细胞核并与 TRAIL 基因启动子结合(Allen 等人,Science Translational Medicine,In Press,2013) )。我们假设 TIC10 诱导有效的抗肿瘤作用,这需要 Akt 和 ERK 介导的 Foxo3a 核转位和 TRAIL 基因的转录激活。为了解决这一假设,我们提出以下具体目标: 具体目标#1:识别 TIC10 诱导的对 Foxo3a 表达、磷酸化和亚细胞定位的影响;具体目标#2:阐明 Akt 和 ERK 激酶在 TIC10 作用机制中的作用;具体目标#3:确定 FOXO 家族成员对 TRAIL 基因转录的差异调节。这些研究将对 TIC10 如何利用 Foxo3a 实现其有效的抗肿瘤活性产生全面的分子理解,并且还有可能发现具有生物学意义的 Foxo3a 活性的新调控机制。包括原位异种移植物和转基因小鼠以及原发性人类肿瘤标本在内的临床前癌症模型将证实 TIC10 和 Foxo3a 的功效并验证其机制发现。这些研究将共同阐明 Foxo3a 与一流分子 TIC10 的关键和新颖的调控机制,以深入了解其作用机制以及结肠癌疾病进展背景下的临床样本。我们的研究将通过临床前实验室研究的进一步发展,促进新型抗癌治疗剂的临床转化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WAFIK S. EL-DEIRY其他文献
WAFIK S. EL-DEIRY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WAFIK S. EL-DEIRY', 18)}}的其他基金
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy
结直肠癌治疗中针对致癌突变体 p53 信号传导
- 批准号:
8840192 - 财政年份:2014
- 资助金额:
$ 0.55万 - 项目类别:
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy
结直肠癌治疗中针对致癌突变体 p53 信号传导
- 批准号:
8665720 - 财政年份:2014
- 资助金额:
$ 0.55万 - 项目类别:
Targeting the oncogenic mutant p53 signaling in colorectal cancer therapy
结直肠癌治疗中针对致癌突变体 p53 信号传导
- 批准号:
9033082 - 财政年份:2014
- 资助金额:
$ 0.55万 - 项目类别:
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL
TIC10 通过调节 Foxo3a 和 TRAIL 发挥抗肿瘤作用
- 批准号:
9131640 - 财政年份:2013
- 资助金额:
$ 0.55万 - 项目类别:
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway
ONC201/TIC10 通过调节 TRAIL 通路发挥抗肿瘤作用
- 批准号:
9924502 - 财政年份:2013
- 资助金额:
$ 0.55万 - 项目类别:
TIC10 anti-tumor effect through regulation of Foxo3a and TRAIL
TIC10 通过调节 Foxo3a 和 TRAIL 发挥抗肿瘤作用
- 批准号:
9327902 - 财政年份:2013
- 资助金额:
$ 0.55万 - 项目类别:
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway
ONC201/TIC10 通过调节 TRAIL 通路发挥抗肿瘤作用
- 批准号:
10738317 - 财政年份:2013
- 资助金额:
$ 0.55万 - 项目类别:
ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway
ONC201/TIC10 通过调节 TRAIL 通路发挥抗肿瘤作用
- 批准号:
9765925 - 财政年份:2013
- 资助金额:
$ 0.55万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer
卵巢癌中的歧视、生态失调和种族差异的经历
- 批准号:
10371537 - 财政年份:2023
- 资助金额:
$ 0.55万 - 项目类别:
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
精氨酸消耗联合铂类紫杉烷化疗对侵袭性变异前列腺癌 (AVPC) 的影响
- 批准号:
10715329 - 财政年份:2023
- 资助金额:
$ 0.55万 - 项目类别:
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
对免疫检查点抑制剂有持久反应的晚期癌症患者的多机构生存研究
- 批准号:
10714336 - 财政年份:2023
- 资助金额:
$ 0.55万 - 项目类别:
San Diego State University Advancing Cancer Careers for ExceLlence (ACCEL)
圣地亚哥州立大学卓越推进癌症职业 (ACCEL)
- 批准号:
10784133 - 财政年份:2023
- 资助金额:
$ 0.55万 - 项目类别: